Nasal nitric oxide improved by continuous positive airway pressure therapy for upper airway inflammation in obstructive sleep apnea

2016 ◽  
Vol 21 (2) ◽  
pp. 405-410 ◽  
Author(s):  
Satoshi Hamada ◽  
Shuji Tatsumi ◽  
Yoshiki Kobayashi ◽  
Hirotaka Yasuba
Author(s):  
Khue Dang-Thi-Mai ◽  
Nhat-Nam Le-Dong ◽  
Khue Bui-Diem ◽  
Quan Vu-Tran-Thien ◽  
Vinh Nguyen-Nhu ◽  
...  

Objective: The aim of the present study was to measure the correlation between the level of exhaled Nitric Oxide (NO) and Obstructive Sleep Apnea (OSA) severity and to evaluate its modification after Continuous Positive Airway Pressure (CPAP) treatment in severe OSA patients. Methods: It was a descriptive and cross-sectional study. Subjects were classified by mild-moderate or severe OSA. CPAP was used for severe OSA patients and followed up for 3 months. Exhaled NO was measured in the morning after the previous night of Respiratory Polygraphy (RPG) recording. Results: This study recruited 123 subjects, including 40 mild-moderate and 83 severe OSA patients. The level of maximum bronchial NO production (J’awNO) in patients with severe OSA was significantly higher than mild-moderate OSA [36.2 (6.1–92.2) vs. 19.6 (1.6-73.0) ppb; p=0.001)]. The level of concentration of NO in the gas phase of the alveolar (CANO) in patients with severe OSA was lower than mild-moderate OSA [5.2 (1.2-12.7) vs. 6.9 (0.8-14.0) ppb; p=0.002). The total flux of NO in the conducting airway compartment (J’awNO) and CANO were correlated with an apnea-hypopnea index (AHI) (rho=0.25 and p=0.02; rho= 0.18 and p=0.04, respectively). There was a weak significant correlation between J’awNO and nadir SpO2 in patients with OSA (rho = -0.22 and p= 0.023). After 3-month treatment with CPAP, the level of J’awNO was significantly reduced in patients with severe OSA [23.4 (12.9-44.5) vs. 33.1 (21.2-55.0); p<0.001. Conclusion: J'awNO is proportionally increased in patients with severe OSA and reduced after treatment with CPAP. Thus, J’awNO may be used as a relevant and surrogate biomarker of severe OSA.


2021 ◽  
Vol 22 (5) ◽  
pp. 2300
Author(s):  
Ronni Baran ◽  
Daniela Grimm ◽  
Manfred Infanger ◽  
Markus Wehland

Obstructive sleep apnea (OSA) is a common disease, with approximately 3–7% of men and 2–5% of women worldwide suffering from symptomatic OSA. If OSA is left untreated, hypoxia, microarousals and increased chemoreceptor stimulation can lead to complications like hypertension (HT). Continuous positive airway pressure (CPAP) is the most common treatment for OSA, and it works by generating airway patency, which will counteract the apnea or hypopnea. More than one billion people in the world suffer from HT, and the usual treatment is pharmacological with antihypertensive medication (AHM). The focus of this review will be to investigate whether the CPAP therapy for OSA affects HT.


Sign in / Sign up

Export Citation Format

Share Document